Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost Acquires 50,000 Shares

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 50,000 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were bought at an average cost of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 1,838,551 shares of the company’s stock, valued at approximately $1,746,623.45. This trade represents a 2.80% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, December 30th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $19,400.00.
• On Friday, December 26th, Phillip Md Et Al Frost purchased 40,000 shares of Cocrystal Pharma stock. The shares were purchased at an average cost of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost acquired 25,000 shares of Cocrystal Pharma stock. The stock was acquired at an average price of $0.97 per share, for a total transaction of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost bought 4,000 shares of Cocrystal Pharma stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was bought at an average cost of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Stock Up 1.4%

NASDAQ:COCP opened at $0.99 on Friday. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.31. The firm has a market capitalization of $13.68 million, a P/E ratio of -1.06 and a beta of 1.13. Cocrystal Pharma, Inc. has a 12-month low of $0.90 and a 12-month high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. As a group, equities research analysts expect that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.